Zabrina Watkins named diversity, equity, and inclusion director for Prime TherapeuticsMarch 28, 2022
Prime Therapeutics (Prime) recently named Zabrina Watkins its new diversity, equity and inclusion (DEI) director.
“At Prime, we’re committed to fostering a culture of inclusion, where everyone feels they can belong and thrive,” said Watkins. “This year we published our first DEI transparency report, highlighting steps we’ve taken toward enhancing workplace inclusion and pledging to continue this important journey,” Watkins added.
Effective March 1, 2022, Watkins assumed the role to build on current and future DEI initiatives for Prime. At Prime, Watkins previously served as co-chair for Prime’s Diversity & Inclusion (D&I) Council and now serves on its Alumni Board. Watkins also currently serves as a lead for Prime’s Black Professionals + Allies employee resource group.
“I am humbled to take on the role of DEI director,” Watkins said. “And I look forward to continuing to build upon the solid foundation and framework for strategies, programs and initiatives that reinforce Prime’s commitment to a more equitable and inclusive organization.”
Prime’s commitment to diversity, equity and inclusion is rooted in its collective values as a company and inseparable from Prime’s purpose and dedication to serving others. Going forward, Prime will further its mission to champion DEI awareness, outreach and events, engaging its employees on a journey toward making workplace inclusion a part of its DNA.
May 13, 2022
Prime Therapeutics’ (Prime) Chris Ford, assistant vice president, strategy and innovation, was a…
April 18, 2022
PrimeCares 2021 Annual Statement
March 31, 2022
The American Pharmacists Association (APhA) awarded Ben Urick, PharmD, PhD, principal health outcomes…